These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29563377)

  • 21. Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.
    Frere C; Laine M; Lemesle G; Morange PE; Paganelli F; Dignat-George F; Resseguier N; Guieu R; Camoin-Jau L; Bonello L
    Platelets; 2019; 30(1):105-111. PubMed ID: 29172822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials.
    Cavender MA; Sabatine MS
    Lancet; 2014 Aug; 384(9943):599-606. PubMed ID: 25131979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fondaparinux: results from an international, multicenter, randomized pilot study (SWITCH III).
    Waksman R; Bertrand O; Driesman M; Gruberg L; Rossi J; Mehta S; Swymelar S; Dvir D; Xue Z; Torguson R
    J Interv Cardiol; 2013 Apr; 26(2):107-13. PubMed ID: 23240743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bivalirudin during primary PCI in acute myocardial infarction.
    Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
    N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents.
    Rha SW; Kuchulakanti PK; Pakala R; Cheneau E; Pinnow E; Gebreeyesus A; Aggrey G; Pichard AD; Satler LF; Kent KM; Lindsay J; Waksman R
    Cardiovasc Radiat Med; 2004; 5(2):64-70. PubMed ID: 15464942
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
    Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC
    Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
    Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
    Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
    EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study.
    Zhang Y; Zhang Y; Chang C; Yan S; Chen Z; Zhang L; Chen K; Liu G
    Clin Ther; 2021 May; 43(5):844-851. PubMed ID: 33810894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding risk and outcomes of Bivalirudin versus Glycoprotein IIb/IIIa inhibitors with targeted low-dose unfractionated Heparin in patients having percutaneous coronary intervention for either stable or unstable angina pectoris.
    Steinberg DH; Shah P; Kinnaird T; Pinto Slottow TL; Roy PK; Okabe T; Bonello L; de Labriolle A; Smith KA; Torguson R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Lindsay J; Waksman R
    Am J Cardiol; 2008 Jul; 102(2):160-4. PubMed ID: 18602514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bivalirudin versus Heparin plus Glycoprotein IIb/IIIa Inhibitors in Women Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials.
    Xu H; Wang B; Yang J; Ma S; Xie X
    PLoS One; 2017; 12(1):e0169951. PubMed ID: 28095453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heparin Versus Bivalirudin in Contemporary Percutaneous Coronary Intervention: A Welcome Back to an Old Friend Unfractionated Heparin.
    Centurión OA
    Crit Pathw Cardiol; 2015 Jun; 14(2):62-6. PubMed ID: 26102015
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial.
    Lincoff AM; Kleiman NS; Kereiakes DJ; Feit F; Bittl JA; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
    JAMA; 2004 Aug; 292(6):696-703. PubMed ID: 15304466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention.
    Shah R; Rogers KC; Matin K; Askari R; Rao SV
    Am Heart J; 2016 Jan; 171(1):14-24. PubMed ID: 26699596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bivalirudin or heparin in primary angioplasty performed through the transradial approach: results from a multicentre registry.
    Sciahbasi A; Rigattieri S; Cortese B; Belloni F; Russo C; Ferraironi A; Tespili M; Angeletti C; Ricci R; Bondanini F; Pugliese FR
    Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):268-74. PubMed ID: 24399486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
    Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
    BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.